Ardsley Advisory Partners purchased a new stake in shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 8,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,056,000.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Ellington Management Group LLC purchased a new stake in shares of GW Pharmaceuticals PLC- during the 4th quarter valued at about $1,373,000. Deutsche Bank AG increased its stake in GW Pharmaceuticals PLC- by 233.5% in the fourth quarter. Deutsche Bank AG now owns 228,206 shares of the biopharmaceutical company’s stock worth $30,124,000 after purchasing an additional 159,783 shares during the period. Tekla Capital Management LLC purchased a new stake in GW Pharmaceuticals PLC- in the fourth quarter worth $3,300,000. Quantitative Investment Management LLC purchased a new stake in GW Pharmaceuticals PLC- in the fourth quarter worth $3,854,000. Finally, Fred Alger Management Inc. increased its stake in GW Pharmaceuticals PLC- by 92.1% in the fourth quarter. Fred Alger Management Inc. now owns 43,256 shares of the biopharmaceutical company’s stock worth $5,710,000 after purchasing an additional 20,735 shares during the period. 82.67% of the stock is owned by hedge funds and other institutional investors.
A number of research firms have weighed in on GWPH. Leerink Swann increased their target price on GW Pharmaceuticals PLC- from $153.00 to $157.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 6th. BidaskClub lowered GW Pharmaceuticals PLC- from a “hold” rating to a “sell” rating in a research note on Friday, March 2nd. Zacks Investment Research lowered GW Pharmaceuticals PLC- from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. Bank of America cut their price target on GW Pharmaceuticals PLC- from $154.00 to $149.00 and set a “buy” rating on the stock in a research note on Tuesday, February 6th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $192.00 price target (down previously from $208.00) on shares of GW Pharmaceuticals PLC- in a research note on Monday, February 5th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company. GW Pharmaceuticals PLC- has a consensus rating of “Hold” and an average price target of $146.38.
GW Pharmaceuticals PLC- (NASDAQ:GWPH) last announced its quarterly earnings results on Monday, February 5th. The biopharmaceutical company reported ($2.43) EPS for the quarter, missing the consensus estimate of ($2.03) by ($0.40). The firm had revenue of $7.73 million for the quarter, compared to analysts’ expectations of $2.18 million. GW Pharmaceuticals PLC- had a negative net margin of 1,357.98% and a negative return on equity of 46.94%. analysts forecast that GW Pharmaceuticals PLC- will post -8.95 EPS for the current year.
WARNING: This story was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/03/13/8000-shares-in-gw-pharmaceuticals-plc-gwph-acquired-by-ardsley-advisory-partners.html.
GW Pharmaceuticals PLC- Company Profile
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.